protein
| F2RL1 and TMED2 interaction occurs between the N-terminal region of TMED2 p24A-GL (GOLD domain with a small linker)) and the second extracellular loop of F2RL1, and after receptor activation, F2RL1 dissociates from TMED2  |
|
collectively, membrane PRTN3 acts as a non-opsonic phagocytosis receptor for bacteria probably by activating F2RL1 in neutrophils  |
|
F3 mediates signalling through coagulation proteases that activate the G-protein-coupled receptors F2R and F2RL1  |
|
KLK14, acting via F2RL1, represents an autocrine/paracrine regulator of colon tumorigenesis  |
|
F3-binding to its ligand F7 induces activation of F2RL1 and this event is thought to considerably influence atherosclerosis and tumor angiogenesis  |
|
F3 participates in protease-activated receptor F2R and F2RL1 activation  |
|
F2RL1 activation generates a signal that induces sustained activation of TRPV4, which requires a key tyrosine residue (TRPV4-Tyr-110)  |
|
ELANE stimulates the secretion of MUC5AC from airway epithelial cells, and can increase F2RL1 expression and MUC5AC release  |
|
extra-pancreatic PRSS3 is produced by esophageal adenocarcinoma (EA) and activates likely F2RL1 in an autocrine manner (F2RL1 activation increases cancer cell proliferation, and promotes cancer cell survival)  |
|
novel functional network of ELANE, secretases, and F2RL1 that regulate CXCR1 expression on neutrophils  |
|
CTSS is a biased agonist of F2RL1 that causes F2RL1- and TRPV4-dependent inflammation and pain  |
|
ELANE activates protease-activated receptor-2 (F2RL1) and transient receptor potential vanilloid 4 (TRPV4) to cause inflammation and pain  |
|
TMPRSS11D displays its physiological functions via protease-activated receptor 2 F2RL1  |
|
TMPRSS11D stimulates IL8 synthesis in airway epithelial cells via F2RL1 and could help to amplify inflammation in chronic respiratory tract disease  |
|
activation of F2RL1 increases expression of BCLl2L12 in lung cancer cells  |